var data={"title":"Zoledronic acid: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Zoledronic acid: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7183?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=zoledronic-acid-patient-drug-information\" class=\"drug drug_patient\">see &quot;Zoledronic acid: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235968\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Reclast;</li>\n      <li>Zometa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235969\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aclasta;</li>\n      <li>Taro-Zoledronic Acid;</li>\n      <li>Taro-Zoledronic Acid Concentrate;</li>\n      <li>Zoledronic Acid  Injection;</li>\n      <li>Zoledronic Acid for Injection;</li>\n      <li>Zoledronic Acid Z;</li>\n      <li>Zometa Concentrate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236015\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Bisphosphonate Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235972\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Acetaminophen administration after the infusion may reduce symptoms of acute-phase reactions. Patients treated for bone metastases from solid tumors, multiple myeloma, and Paget disease should receive a daily calcium and vitamin D supplement, and patients with osteoporosis should receive calcium and vitamin D supplementation if dietary intake is inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Bone metastases from solid tumors (Zometa):</b> IV: 4 mg once every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bone metastases due to breast cancer or prostate cancer (off-label dosing):</b> IV: 4 mg once every 12 weeks; dosing once every 12 weeks (compared to once every 4 weeks) did not result in an increased risk of skeletal events within 2 years in patients with at least 1 site of bone involvement (Himmelstein 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypercalcemia of malignancy (albumin-corrected serum calcium &ge;12 mg/dL) (Zometa):</b> IV: 4 mg (maximum) given as a single dose. Wait at least 7 days before considering re-treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma osteolytic lesions (Zometa):</b> IV: 4 mg once every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Multiple myeloma (off-label dosing):</b> IV: 4 mg once every 12 weeks; dosing once every 12 weeks (compared to once every 4 weeks) did not result in an increased risk of skeletal events within 2 years in patients with at least 1 site of bone involvement (Himmelstein 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis, glucocorticoid-induced, treatment and prevention (Reclast, Aclasta [Canadian product]):</b> Females or males: IV: 5 mg once a year</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis, prevention: </b>Postmenopausal females: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reclast:</b> 5 mg once every 2 years</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Aclasta [Canadian product]: </b>5 mg as a single (one-time) dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis, treatment (Reclast, Aclasta [Canadian product]): </b>Males or postmenopausal females: IV: 5 mg once a year. <b>Note: </b>The optimal duration of treatment has not been determined. In postmenopausal women with low fracture risk, consider a drug holiday after 3 years of IV bisphosphonate use. In postmenopausal women who remain at high fracture risk consider extending treatment for up to 6 years (AACE/ACE [Camacho 2016]; Adler 2016). Although evidence is limited, applying these recommendations to treatment duration in older men may be considered (Adler 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paget disease (Reclast, Aclasta [Canadian product]):</b> IV: 5 mg as a single dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Re-treatment: Data concerning retreatment is not available; retreatment may be considered for relapse (increase in alkaline phosphatase) if appropriate, for inadequate response, or in patients who are symptomatic. An interval of at least 1 year from initial treatment has been recommended when considering retreatment for relapse (Aclasta Canadian product labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The Endocrine Society guidelines suggest re-treatment is seldom required within 5 years (Singer 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postrenal transplant bone loss (prevention) (off-label use): </b>IV: 4 mg at week 2 and month 3 after engraftment (Haas 2003; Schwarz 2004). Additional data may be necessary to further define the role of zoledronic acid in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone loss associated with androgen deprivation therapy in prostate cancer, prevention (off-label use):</b> IV: 4 mg once every 3 months for 1 year (Smith, 2003) or 4 mg every 12 months (Michaelson 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone loss associated with aromatase inhibitor therapy in women with breast cancer, prevention (off-label use):</b> IV: 4 mg once every 6 months for 5 years (Brufsky 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235973\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235974\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Prior to each dose, obtain serum creatinine and calculate the creatinine clearance using the Cockcroft-Gault formula.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Nononcology uses: </i></b>\n      <b>Note:</b> Use actual body weight in the Cockcroft-Gault formula when calculating clearance for nononcology uses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;35 mL/minute: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;35 mL/minute: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Oncology uses:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Multiple myeloma and bone metastases:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;60 mL/minute: 4 mg (no dosage adjustment is necessary)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 50 to 60 mL/minute: Reduce dose to 3.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 40 to 49 mL/minute: Reduce dose to 3.3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 39 mL/minute: Reduce dose to 3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypercalcemia of malignancy:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate impairment: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment (serum creatinine &gt;4.5 mg/dL): Evaluate risk versus benefit</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for renal toxicity (during treatment):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypercalcemia of malignancy: Evidence of renal deterioration: Evaluate risk versus benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Multiple myeloma and bone metastases: Evidence of renal deterioration: Withhold dose until renal function returns to within 10% of baseline; renal deterioration defined as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Normal baseline creatinine: Increase of 0.5 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Abnormal baseline creatinine: Increase of 1 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Reinitiate therapy at the same dose administered prior to treatment interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Multiple myeloma: Albuminuria &gt;500 mg/24 hours (unexplained): Withhold dose until return to baseline, then reevaluate every 3 to 4 weeks; consider reinitiating with a longer infusion time of at least 30 minutes (Kyle 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235975\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); however, zoledronic acid is not metabolized hepatically. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235946\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zometa: 4 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Reclast: 5 mg/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zometa: 4 mg/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/100 mL (100 mL); 5 mg/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/100 mL (100 mL); 5 mg/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg (1 ea [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235932\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10076370\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Concentrate, Intravenous:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zometa: 4 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infusion, Solution [premixed]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aclasta: 5 mg/100 mL (100 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11441699\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Reclast: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021817s027lbl.pdf#page=25&amp;token=d/CTJ1lvsXrYqtQkgRWBEZSFO5zE6S0WdnthBVwHsFh8w6HxC8cdBNo6hBvRiTBWB+0MOncnx4+Lba68x7DV0SWhZZbHOj4cUnKwvYJHTcw9scKu8+3fj7eJ5Cbi2EiN&amp;TOPIC_ID=9902\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021817s027lbl.pdf#page=25</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235948\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: If refrigerated, allow solution to reach room temperature before administration. Infuse over at least 15 minutes. Flush IV line with 10 mL NS flush following infusion. Infuse in a line separate from other medications. Patients must be appropriately hydrated prior to treatment. Acetaminophen after administration may reduce the incidence of acute reaction (eg, arthralgia, fever, flu-like symptoms, myalgia).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multiple myeloma: If treatment is withheld for unexplained albuminuria, consider increasing the infusion time to at least 30 minutes upon reinitiation (Kyle 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132718\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) if compounding. Double gloving and a gown are required during administration (NIOSH 2016). Premixed solutions may be excluded from some hazardous drug handling requirements; assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235947\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone metastases from solid tumors (Zometa):</b> Treatment of documented bone metastases from solid tumors (in conjunction with standard antineoplastic therapy); prostate cancer should have progressed following treatment with at least one hormonal therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glucocorticoid-induced osteoporosis (Reclast, Aclasta [Canadian product]):</b> Treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are initiating or continuing systemic glucocorticoids in a daily dose equivalent to 7.5 mg or more of prednisone and who are expected to remain on glucocorticoids for at least 12 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypercalcemia of malignancy (Zometa):</b> Treatment of hypercalcemia (albumin-corrected serum calcium &ge;12 mg/dL) of malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma (Zometa):</b> Treatment of osteolytic lesions of multiple myeloma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis in men (Reclast, Aclasta [Canadian product]):</b> To increase bone mass in men with osteoporosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paget disease of bone (Reclast, Aclasta [Canadian product]):</b> Treatment of Paget disease of bone in men and women. <b>Note:</b> In patients without contraindications, zoledronic acid is recommended as the treatment of choice per Endocrine Society guidelines (Singer 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postmenopausal osteoporosis (Reclast, Aclasta [Canadian product]):</b> Treatment and prevention of osteoporosis in postmenopausal women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Limitations of use: Safety and efficacy for treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions have not been established. Safety and efficacy for osteoporosis treatment is based on clinical data of 3 years duration; the optimal duration has not been determined. All patients on bisphosphonate therapy for the treatment of osteoporosis should be re-evaluated periodically for the need to continue therapy; consider discontinuing after 3 to 5 years in patients at low-risk for fracture; re-evaluate fracture risk periodically in patients who discontinue therapy.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25484313\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bone loss associated with androgen deprivation therapy in prostate cancer (prevention); Bone loss associated with aromatase inhibitor therapy in women with breast cancer (prevention); Postrenal transplant bone loss (prevention)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6136763\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zometa may be confused with Jevtana, Xgeva, Xofigo, Xtandi, Zofran, Zoladex, Zytiga</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Duplicate therapy issues: Reclast and Aclasta contain zoledronic acid, which is the same ingredient contained in Zometa; patients receiving Zometa should not be treated with Reclast or Aclasta </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235938\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oncology indications:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Lower extremity edema (5% to 21%), hypotension (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (39%), headache (5% to 19%), dizziness (18%), insomnia (15% to 16%), depression (14%), anxiety (11% to 14%), agitation (13%), confusion (7% to 13%), hypoesthesia (12%), rigors (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (12%), dermatitis (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration (5% to 14%), hypophosphatemia (13%), hypokalemia (12%), hypomagnesemia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (29% to 46%), vomiting (14% to 32%), constipation (27% to 31%), diarrhea (17% to 24%), anorexia (9% to 22%), weight loss (16%), abdominal pain (14% to 16%), decreased appetite (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (12% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (22% to 33%), progression of cancer (16% to 20%), neutropenia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Candidiasis (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Ostealgia (55%), weakness (5% to 24%), myalgia (23%), arthralgia (5% to 21%), back pain (15%), paresthesia (15%), limb pain (14%), skeletal pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency (8% to 17%; up to 40% in patients with abnormal baseline creatinine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (22% to 27%), cough (12% to 22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (32% to 44%; most common symptom of acute phase reaction)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (5% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Somnolence (5% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypocalcemia (5% to 10%; grades 3/4: &le;1%), hypermagnesemia (grade 3: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (10%), dysphagia (5% to 10%), mucositis (5% to 10%), sore throat (8%), stomatitis (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Granulocytopenia (5% to 10%), pancytopenia (5% to 10%), thrombocytopenia (5% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (nonspecific; 5% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (grades 3/4: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nononcology indications:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (5% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (2% to 24%), fever (9% to 22%), headache (4% to 20%), chills (2% to 18%), fatigue (2% to 18%), flank pain (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypocalcemia (&le;3%; Paget disease 21%), dehydration (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (5% to 18%), upper abdominal pain (5%), abdominal distension (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Infusion-related reaction (4% to 25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (9% to 27%), myalgia (5% to 23%), back pain (4% to 18%), limb pain (3% to 16%), musculoskeletal pain (&le;12%), osteoarthritis (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (1% to 8%), peripheral edema (3% to 6%), atrial fibrillation (1% to 3%), palpitations (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (2% to 9%), rigors (8%), malaise (1% to 7%), hypoesthesia (&le;6%), lethargy (3% to 5%), vertigo (1% to 4%), paresthesia (2%), hyperthermia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (2% to 3%), hyperhidrosis (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (1% to 9%), diarrhea (5% to 8%), vomiting (2% to 8%), constipation (6% to 7%), dyspepsia (2% to 7%), abdominal discomfort (1% to 2%), anorexia (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Change in serum protein (C-reactive protein increased; &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Ostealgia (3% to 9%), arthritis (2% to 9%), neck pain (1% to 7%), shoulder pain (&le;7%), muscle spasm (2% to 6%), weakness (2% to 6%), stiffness (1% to 5%), jaw pain (2% to 4%), joint swelling (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye pain (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (5% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>All indications:</b> &lt;1%, postmarketing, and/or case reports: Acute phase reaction-like symptoms (including pyrexia, fatigue, bone pain, arthralgia, myalgia, chills, influenza-like illness; usually resolves within 3 to 4 days of onset, although may take up to 14 days to resolve), acute renal failure (requiring hospitalization/dialysis), acute renal tubular necrosis (toxic), anaphylactic shock, anaphylaxis, angioedema, arthralgia (sometimes severe and/or incapacitating), blurred vision, bradycardia, bronchoconstriction, bronchospasm, cardiac arrhythmia, cerebrovascular accident, conjunctivitis, diaphoresis, drowsiness, dysgeusia, episcleritis, exacerbation of asthma, Fanconi syndrome (acquired), femur fracture (diaphyseal or subtrochanteric), hematuria, hyperesthesia, hyperkalemia, hypernatremia, hyperparathyroidism, hypersensitivity reaction, hypertension, injection site reaction (eg, itching, pain, redness), interstitial pulmonary disease, iridocyclitis, iritis, muscle cramps, myalgia (sometimes severe and/or incapacitating), numbness, osteonecrosis (including external auditory canal, femur, and hip), osteonecrosis of the jaw, periorbital edema, periorbital swelling, prolonged QT interval on ECG, proteinuria, pruritus, renal insufficiency, scleritis, seizure, skin rash, Stevens-Johnson syndrome, tetany, toxic epidermal necrolysis, tremor, urticaria, uveitis, weight gain, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235951\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity to zoledronic acid or any component of the formulation; hypocalcemia (Reclast only); CrCl &lt;35 mL/minute and in those with evidence of acute renal impairment (Reclast only).</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">All indications: Hypersensitivity to zoledronic acid or other bisphosphonates, or any component of the formulation; uncorrected hypocalcemia at the time of infusion; pregnancy, breast-feeding</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Nononcology uses: Additional contraindications: Use in patients with CrCl &lt;35 mL/minute and use in patients with evidence of acute renal impairment due to an increased risk of renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Documentation of allergenic cross-reactivity for bisphosphonates is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235936\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone fractures: Atypical femur fractures (AFF) have been reported in patients receiving bisphosphonates. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures; atypical femur fractures have also been reported in patients not taking bisphosphonates, and in patients receiving glucocorticoids. Patients receiving long-term (&gt;3 to 5 years) bisphosphonate therapy may be at an increased risk (Adler 2016; NOF [Cosman 2014]); however, benefits of therapy (when used for osteoporosis) generally outweigh absolute risk of AFF within the first 5 years of treatment (Adler 2016). Patients presenting with thigh or groin pain with a history of receiving bisphosphonates should be evaluated for femur fracture. Consider interrupting bisphosphonate therapy in patients who develop a femoral shaft fracture; assess for fracture in the contralateral limb.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Rare cases of urticaria and angioedema and very rare cases of anaphylactic reactions/shock have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: Hypocalcemia (including severe and life-threatening cases) has been reported with use; patients with Paget disease may be at significant risk for hypocalcemia after treatment with zoledronic acid (because pretreatment rate of bone turnover may be elevated); severe and life-threatening hypocalcemia has also been reported with oncology-related uses. Measure serum calcium prior to treatment initiation. Correct preexisting hypocalcemia before initiation of therapy in patients with Paget disease, osteoporosis, or oncology indications. Use with caution with other medications known to cause hypocalcemia (severe hypocalcemia may develop). Ensure adequate calcium and vitamin D supplementation during therapy. Use caution in patients with disturbances of calcium and mineral metabolism (eg, hypoparathyroidism, thyroid/parathyroid surgery, malabsorption syndromes, excision of small intestine). QTc prolongation, cardiac arrhythmias, and neurologic events (eg, tetany, tonic-clonic seizures, numbness) secondary to severe hypocalcemia have been reported 1 day to several months after initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Musculoskeletal pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular infection: Conjunctivitis, uveitis, episcleritis, iritis, scleritis, and orbital inflammation have been reported (infrequently) with use; further ophthalmic evaluation (and possibly therapy discontinuation) may be necessary in patients with complicated infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates. Known risk factors for MRONJ include invasive dental procedures (eg, tooth extraction, dental implants, bony surgery), cancer diagnosis, concomitant therapy (eg, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, ill-fitting dentures, and comorbid disorders (anemia, coagulopathy, infection, preexisting dental disease). Risk may increase with duration of bisphosphonate use and/or may be reported at a greater frequency based on tumor type (eg, advanced breast cancer or multiple myeloma). According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonates and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy; risk is significantly higher in cancer patients receiving antiresorptive therapy compared to patients receiving osteoporosis treatment (regardless of medication used or dosing schedule). MRONJ risk is also increased with monthly IV antiresorptive therapy compared to the minimal risk associated with oral bisphosphonate use, although risk appears to increase with oral bisphosphonates when duration of therapy exceeds 4 years. The manufacturer&rsquo;s labeling states that there are no data to suggest whether discontinuing bisphosphonates in patients requiring invasive dental procedures reduces the risk of ONJ. The manufacturer recommends a dental exam and preventive dentistry be performed prior to placing patients with risk factors on chronic bisphosphonate therapy and that during therapy, invasive dental procedures be avoided, if possible. The AAOMS suggests that if medically permissible, initiation of IV bisphosphonates for cancer therapy should be delayed until optimal dental health is attained (if extractions are required, antiresorptive therapy should delayed until the extraction site has mucosalized or until after adequate osseous healing). Once IV bisphosphonate therapy is initiated for oncologic disease, procedures that involve direct osseous injury and placement of dental implants be avoided. Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aspirin-sensitive asthma: Use with caution in patients with aspirin-sensitive asthma; may cause bronchoconstriction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Breast cancer (metastatic): The American Society of Clinical Oncology (ASCO) updated guidelines on the role of bone-modifying agents (BMAs) in the prevention and treatment of skeletal-related events for metastatic breast cancer patients (Van Poznak, 2011). The guidelines recommend initiating a BMA (denosumab, pamidronate, zoledronic acid) in patients with metastatic breast cancer to the bone. There is currently no literature indicating the superiority of one particular BMA. Optimal duration is not yet defined; however, the guidelines recommend continuing therapy until substantial decline in patient&rsquo;s performance status. The ASCO guidelines are in alignment with prescribing information for dosing, renal dose adjustments, infusion times, prevention and management of osteonecrosis of the jaw, and monitoring of laboratory parameter recommendations. BMAs are not the first-line therapy for pain. BMAs are to be used as adjunctive therapy for cancer-related bone pain associated with bone metastasis, demonstrating a modest pain control benefit. BMAs should be used in conjunction with agents such as NSAIDS, opioid and nonopioid analgesics, corticosteroids, radiation/surgery, and interventional procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: The American Society of Clinical Oncology (ASCO) has published guidelines on bisphosphonate use for prevention and treatment of bone disease in multiple myeloma (Kyle, 2007). Bisphosphonate (pamidronate or zoledronic acid) use is recommended in multiple myeloma patients with lytic bone destruction or compression spine fracture from osteopenia. Bisphosphonates may also be considered in patients with pain secondary to osteolytic disease, adjunct therapy to stabilize fractures or impending fractures, and for multiple myeloma patients with osteopenia but no radiographic evidence of lytic bone disease. Bisphosphonates are not recommended in patients with solitary plasmacytoma, smoldering (asymptomatic) or indolent myeloma, or monoclonal gammopathy of undetermined significance. The guidelines recommend monthly treatment for a period of 2 years. At that time, consider discontinuing in responsive and stable patients, and reinitiate if a new-onset skeletal-related event occurs. The ASCO guidelines are in alignment with prescribing information for dosing, renal dose adjustments, infusion times, prevention and management of osteonecrosis of the jaw, and monitoring of laboratory parameter recommendations. According to the guidelines, in patients with a serum creatinine &gt;3 mg/dL or CrCl &lt;30 mL/minute or extensive bone disease, an alternative bisphosphonate (pamidronate) should be used. Monitor for albuminuria every 3 to 6 months; in patients with unexplained albuminuria &gt;500 mg/24 hours, withhold the dose until level returns to baseline, then recheck every 3 to 4 weeks. Upon reinitiation, the guidelines recommend considering increasing the zoledronic acid infusion time to at least 30 minutes; however, one study has demonstrated that extending the infusion to 30 minutes did not change the safety profile (Berenson, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in mild to moderate renal impairment. Single and multiple infusions in patients with both normal and impaired renal function have been associated with renal deterioration, resulting in renal failure and dialysis (rare). Preexisting renal compromise, severe dehydration, and concurrent use with diuretics or other nephrotoxic drugs may increase the risk for renal impairment. Adequate hydration is required during treatment (urine output ~2 L/day); avoid overhydration, especially in patients with heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Nononcology indications: </i> Use is contraindicated in patients with CrCl &lt;35 mL/minute and in patients with evidence of acute renal impairment. Do not use single doses &gt;5 mg and do not infuse over less than 15 minutes. Patients with underlying moderate to severe renal impairment, increased age, concurrent use of nephrotoxic or diuretic medications, or severe dehydration prior to or after zoledronic acid administration may have an increased risk of acute renal impairment or renal failure. Others with increased risk include patients with renal impairment or dehydration secondary to fever, sepsis, gastrointestinal losses, or diuretic use. If history or physical exam suggests dehydration, treatment should not be given until the patient is normovolemic. Obtain serum creatinine and calculate creatinine clearance (using actual body weight) with the Cockcroft-Gault formula prior to each administration. Transient increases in serum creatinine may be more pronounced in patients with impaired renal function; monitoring creatinine clearance in at-risk patients taking other renally eliminated drugs is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Oncology indications:</i> Dosage adjustment required with renal impairment. Use is not recommended in patients with severe renal impairment (serum creatinine &gt;3 mg/dL or CrCl &lt;30 mL/minute) and bone metastases (limited data); use in patients with hypercalcemia of malignancy and severe renal impairment (serum creatinine &gt;4.5 mg/dL for hypercalcemia of malignancy) should only be done if the benefits outweigh the risks. In cancer patients, do not use single doses &gt;4 mg and do not infuse over less than 15 minutes (renal toxicity has been reported with doses &gt;4 mg or infusions administered over less than 15 minutes). Risk factors for renal deterioration include preexisting renal insufficiency and repeated doses and other bisphosphonates therapy. Dehydration and the use of other nephrotoxic drugs which may contribute to renal deterioration should be identified and managed. Diuretics should not be used before correcting hypovolemia. Assess renal function (eg, serum creatinine) prior to each dose and withhold for renal deterioration (increase in serum creatinine of 0.5 mg/dL [if baseline level normal] or increase of 1 mg/dL [if baseline level abnormal]); treatment should be withheld until renal function returns to within 10% of baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Because decreased renal function occurs more commonly in elderly patients, take special care to monitor renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duplicate therapy: Do not administer Zometa and Reclast (Aclasta [Canadian product]) to the same patient for different indications.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300240\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235940\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9902&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitonin: May enhance the hypocalcemic effect of Zoledronic Acid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: May enhance the adverse/toxic effect of Zoledronic Acid.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235942\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235954\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. It is not known if bisphosphonates cross the placenta, but fetal exposure is expected (Djokanovic, 2008; Stathopoulos, 2011). Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by dose and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy; however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic, 2008; Levy, 2009; Stathopoulos, 2011). Until additional data is available, most sources recommend discontinuing bisphosphonate therapy in women of reproductive potential as early as possible prior to a planned pregnancy; use in premenopausal women should be reserved for special circumstances when rapid bone loss is occurring (Bhalla, 2010; Pereira, 2012;  Stathopoulos, 2011). Because hypocalcemia has been described following <i>in utero</i> bisphosphonate exposure, exposed infants should be monitored for hypocalcemia after birth (Djokanovic, 2008; Stathopoulos, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2998081\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if zoledronic acid is excreted into breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235955\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multiple myeloma or metastatic bone lesions from solid tumors: Take daily calcium supplement (500 mg) and daily multivitamin (with 400 units vitamin D).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osteoporosis: Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Women and men should consume:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Calcium: 1,000 mg/day (men: 50 to 70 years) <b>or</b> 1200 mg/day (women &ge;51 years and men &ge;71 years) (IOM 2011; NOF [Cosman 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vitamin D: 800 to 1,000 int. units/day (men and women &ge;50 years) (NOF 2014). Recommended Dietary Allowance (RDA): 600 int. units/day (men and women &le;70 years) <b>or</b> 800 int. units/day (men and women &ge;71 years) (IOM 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paget disease: Take elemental calcium 1500 mg/day (750 mg twice daily or 500 mg 3 times/day) and vitamin D 800 units/day, particularly during the first 2 weeks after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235944\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Prior to initiation of therapy, dental exam and preventive dentistry for patients at risk for osteonecrosis, including all cancer patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nononcology uses: Serum creatinine prior to each dose, especially in patients with risk factors, calculate creatinine clearance before each treatment (consider interim monitoring in patients at risk for acute renal failure), evaluate fluid status and adequately hydrate patients prior to and following administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Osteoporosis: Bone mineral density (BMD) should be evaluated 1 to 2 years after initiating therapy and every 1 to 2 years (or less frequently if stable) thereafter (AACE/ACE [Camacho 2016]; NOF [Cosman 2014]); in patients with combined zoledronic acid and glucocorticoid treatment, evaluate BMD at initiation of glucocorticoid therapy and after 6 to 12 months, then every 2 to 3 years if patient continues to have significant osteoporosis risk factors (ACR [Buckley 2017]); serum calcium and 25(OH)D; annual measurements of height and weight, assessment of chronic back pain; serum calcium and 25(OH)D; phosphorus and magnesium; may consider monitoring biochemical markers of bone turnover</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Paget disease: Alkaline phosphatase at 6 to 12 weeks for initial response to treatment (when bone turnover will have shown a substantial decline) and potentially at 6 months (maximal suppression of high bone turnover); following treatment completion, monitor at ~1- to 2-year intervals (Singer, 2014); monitoring more specific biochemical markers of bone turnover (eg, serum P1NP, NTX, serum beta-CTx) is generally only warranted in patients with Paget disease who have abnormal liver or biliary tract function or when early assessment of response to treatment is needed (eg, spinal compression, very active disease) (Singer, 2014); serum calcium and 25(OH)D; phosphorus and magnesium; symptoms of hypocalcemia, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oncology uses: Serum creatinine prior to each dose; serum electrolytes, phosphate, magnesium, and hemoglobin/hematocrit should be evaluated regularly. Monitor serum calcium to assess response and avoid overtreatment. In patients with multiple myeloma, monitor urine every 3 to 6 months for albuminuria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21303677\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium (total): Adults: 9 to 11 mg/dL (2.05 to 2.54 mmol/L), may slightly decrease with aging</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus: 2.5 to 4.5 mg/dL (0.81 to 1.45 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D: There is no clear consensus on a reference range for total serum 25(OH)D concentrations or the validity of this level as it relates clinically to bone health. In addition, there is significant variability in the reporting of serum 25(OH)D levels as a result of different assay types in use; however, the following ranges have been suggested:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults (IOM 2011): Sufficient levels in practically all persons: &ge;20 ng/mL (50 nmol/L); concern for risk of toxicity: &gt;50 ng/mL (125 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Osteoporosis patients (NOF [Cosman 2014]): Recommended level to reach and maintain: ~30 ng/mL (75 nmol/L) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235935\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A bisphosphonate which inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; inhibits osteoclastic activity and skeletal calcium release induced by tumors. Decreases serum calcium and phosphorus, and increases their elimination. In osteoporosis, zoledronic acid inhibits osteoclast-mediated resorption, therefore reducing bone turnover.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235950\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Binds to bone </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 23% to 53% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily eliminated intact via the kidney; metabolism not likely</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Triphasic; Terminal: 146 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (39% &plusmn; 16% as unchanged drug) within 24 hours; feces (&lt;3%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235953\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (Zoledronic Acid Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/5 mL (5 mL): $360.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (Zometa Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/5 mL (5 mL): $1,106.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Reclast Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/100 mL (100 mL): $1,300.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Zoledronic Acid Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/100 mL (100 mL): $72.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/100 mL (100 mL): $420.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Zometa Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/100 mL (100 mL): $1,106.98</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235956\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aclasta (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, KR, KW, LB, LK, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VN, ZA);</li>\n      <li>Ai Lang (CN);</li>\n      <li>Aklasta (UA);</li>\n      <li>Amonzitra (SG);</li>\n      <li>Blaztere (IN, VN);</li>\n      <li>Bolenic (TW);</li>\n      <li>Bonizol (BD);</li>\n      <li>Drometa (BD);</li>\n      <li>Leuzotev (TH);</li>\n      <li>Osteomet (LK);</li>\n      <li>Reclast (JP);</li>\n      <li>Sinresor (VN);</li>\n      <li>Vexonib-4 (PH);</li>\n      <li>Xoleron (BD);</li>\n      <li>Zerlinda (IE);</li>\n      <li>Zidronic (EC);</li>\n      <li>Zinvel (TH);</li>\n      <li>Zobonic (TW);</li>\n      <li>Zofaden (MX);</li>\n      <li>Zoffec (ID);</li>\n      <li>Zoldonat (SG);</li>\n      <li>Zoldron-4 (PH);</li>\n      <li>Zoled (PH);</li>\n      <li>Zoledran (SG);</li>\n      <li>Zolennic (TH);</li>\n      <li>Zoletalis (PH, VN);</li>\n      <li>Zoltero (BD);</li>\n      <li>Zomegoal (MX);</li>\n      <li>Zomera (IL);</li>\n      <li>Zometa (AE, AR, AT, AU, BB, BE, BG, BH, BO, BR, CH, CL, CN, CY, CZ, DE, DK, EC, EE, FI, FR, GB, GR, HR, HU, ID, IE, IT, JO, JP, KR, KW, LB, LK, LT, LU, MT, MX, MY, NL, NO, NZ, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UY, VE, VN, ZA);</li>\n      <li>Zoruxa (TH);</li>\n      <li>Zova (SG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aclasta (zoledronic acid) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research [published correction appears in <i>J Bone Miner Res</i>. 2016;31(10):1910]. <i>J Bone Miner Res</i>. 2016;31(1):16-35. doi: 10.1002/jbmr.2708.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/26350171/pubmed\" target=\"_blank\" id=\"26350171\">26350171</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Dental Association Council on Scientific Affairs, &ldquo;Dental Management of Patients Receiving Oral Bisphosphonate Therapy,&rdquo; JADA, 2006, 137(8):1144-50. Available at http://jada.ada.org/article/S0002-8177(14)64960-6/pdf16873332</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berenson JR, Boccia R, Lopez T, et al, &ldquo;Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial), <i>J Support Oncol</i>, 2011, 9(1):32-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21465735/pubmed\" target=\"_blank\" id=\"21465735\">21465735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhalla AK, &quot;Management of Osteoporosis in a Pre-menopausal Woman,&quot; <i>Best Pract Res Clin Rheumatol</i>, 2010, 24(3):313-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20534366/pubmed\" target=\"_blank\" id=\"20534366\">20534366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Black DM, Delmas PD, Eastell R, et al, &ldquo;Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis,&rdquo; <i>New Engl J Med</i>, 2007, 356(18):1809-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17476007/pubmed\" target=\"_blank\" id=\"17476007\">17476007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Body JJ, &ldquo;Clinical Research Update: Zoledronate,&rdquo; <i>Cancer</i>, 1997, 80(Suppl):1699-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/9362440/pubmed\" target=\"_blank\" id=\"9362440\">9362440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boonen S, Sellmeyer DE, Lippuner K, et al, &ldquo;Renal Safety of Annual Zoledronic Acid Infusions in Osteoporotic Postmenopausal Women,&rdquo; <i>Kidney Int</i>, 2008, 74(5):641-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/18509324/pubmed\" target=\"_blank\" id=\"18509324\">18509324</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brufsky A, Harker WG, Beck JT, et al, &ldquo;Zoledronic Acid Inhibits Adjuvant Letrozole-Induced Bone Loss in Postmenopausal Women With Early Breast Cancer,&rdquo; <i>J Clin Oncol</i> 2007, 25(7):829-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17159193/pubmed\" target=\"_blank\" id=\"17159193\">17159193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21987386\"></a>Brufsky AM, Harker WG, Beck JT, et al, &ldquo;Final 5-year results of Z-FAST Trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole,&rdquo; <i>Cancer</i>, 2012, 118(5):1192-201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21987386/pubmed\" target=\"_blank\" id=\"21987386\">21987386</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis&ndash;2016: executive summary [published correction appears in <i>Endocr Pract. </i>2017;23(3):383]. <i>Endocr Pract</i>. 2016;22(9):1111-1118. doi: 10.4158/EP161435.ESGL.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/27643923/pubmed\" target=\"_blank\" id=\"27643923\">27643923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coleman RE and Seaman JJ, &ldquo;The Role of Zoledronic Acid in Cancer: Clinical Studies in the Treatment and Prevention of Bone Metastases,&rdquo; <i>Semin Oncol</i>, 2001, 28(2 Suppl 6):11-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/11346860/pubmed\" target=\"_blank\" id=\"11346860\">11346860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coleman RE, Marshall H, Cameron D, et al, &ldquo;Breast-Cancer Adjuvant Therapy With Zoledronic Acid,&rdquo; <i>N Engl J Med</i>, 2011, 365(15):1396-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21995387/pubmed\" target=\"_blank\" id=\"21995387\">21995387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi: 10.1007/s00198-014-2794-2.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Djokanovic N, Klieger-Grossmann C, and Koren G, &quot;Does Treatment With Bisphosphonates Endanger the Human Pregnancy?&quot; <i>J Obstet Gynaecol Can</i>, 2008, 30(12):1146-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/19175968/pubmed\" target=\"_blank\" id=\"19175968\">19175968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durie BG, Katz M, and Crowley J, &ldquo;Osteonecrosis of the Jaw and Bisphosphonates,&quot; <i>N Engl J Med</i>, 2005, 353(1):99-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/16000365/pubmed\" target=\"_blank\" id=\"16000365\">16000365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eidtmann H, de Boer R, Bundred N, et al, &ldquo;Efficacy of Zoledronic Acid in Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole: 36-Month Results of the ZO-FAST Study,&rdquo; <i>Ann Oncol</i>, 2010, 21(11):2188-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20444845/pubmed\" target=\"_blank\" id=\"20444845\">20444845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Francini F, Pascucci A, Francini E, et al, &ldquo;Osteonecrosis of the Jaw in Patients With Cancer Who Received Zoledronic Acid and Bevacizumab,&rdquo; <i>J Am Dent Assoc</i>, 2011, 142(5):506-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21531932/pubmed\" target=\"_blank\" id=\"21531932\">21531932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gnant M, Mlineritsch B, Schippinger W, et al, &ldquo;Endocrine Therapy Plus Zoledronic Acid in Premenopausal Breast Cancer,&rdquo; <i>N Engl J Med</i>, 2009, 360(7):679-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/19213681/pubmed\" target=\"_blank\" id=\"19213681\">19213681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grbic JT, Black DM, Lyles KW, et al, &ldquo;The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid: Data From the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Clinical Trials Program,&rdquo; <i>J Am Dent Assoc</i>, 2010, 141(11):1365-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21037195/pubmed\" target=\"_blank\" id=\"21037195\">21037195</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haas M, Leko-Mohr Z, Roschger P, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. <i>Kidney Int</i>. 2003;63(3):1130-1136.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/12631097/pubmed\" target=\"_blank\" id=\"12631097\">12631097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hadji P, Aapro MS, Body JJ, et al, &ldquo;Management of Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Breast Cancer: Practical Guidance for Prevention and Treatment,&rdquo; <i>Ann Oncol</i>, 2011, 22(12):2546-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21415233/pubmed\" target=\"_blank\" id=\"21415233\">21415233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstein JW, Adler RA, Edwards B, et al, &quot;Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Executive Summary of Recommendations From the American Dental Association Council on Scientific Affairs,&quot; <i>J Am Dent Assoc</i>, 2011, 142(11):1243-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/22041409/pubmed\" target=\"_blank\" id=\"22041409\">22041409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstein JW, Adler RA, Edwards B, et al, &quot;Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Recommendations From the American Dental Association Council on Scientific Affairs,&quot; 2011, Available at http://www.ada.org/sections/professionalResources/pdfs/topics_ARONJ_report.pdf. Accessed February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hershman DL, McMahon DJ, Crew KD, et al, &ldquo;Prevention of Bone Loss By Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist Up to One Year Following Discontinuing Treatment,&rdquo; <i>J Clin Endocrinol Metab</i>, 2010, 95(2):559-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20022990/pubmed\" target=\"_blank\" id=\"20022990\">20022990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillner BE, Ingle JN, Chlebowski RT, et al, &ldquo;American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 2003, 21(21):4042-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/12963702/pubmed\" target=\"_blank\" id=\"12963702\">12963702</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. <i>JAMA</i>. 2017;317(1):48-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/28030702/pubmed\" target=\"_blank\" id=\"28030702\">28030702</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D,</i> Washington, DC: The National Academies Press, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>J Bone Miner Res.</i> 2015; 30(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/25414052/pubmed\" target=\"_blank\" id=\"25414052\">25414052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kyle RA, Yee GC, Somerfield MR, et al, &ldquo;American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma,&rdquo; <i>J Clin Oncol</i>, 2007, 25(17):2464-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17515569/pubmed\" target=\"_blank\" id=\"17515569\">17515569</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy S, Fayez I, Taguchi N, et al, &quot;Pregnancy Outcome Following <i>in utero</i> Exposure to Bisphosphonates,&quot; <i>Bone</i>, 2009, 44(3):428-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/19059370/pubmed\" target=\"_blank\" id=\"19059370\">19059370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyles KW, Colon-Emeric CS, Magaziner JS, et al, &ldquo;Zoledronic Acid and Clinical Fractures and Mortality After Hip Fracture,&rdquo; <i>N Engl J Med</i>, 2005, 357(18):1799-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17878149/pubmed\" target=\"_blank\" id=\"17878149\">17878149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maerevoet M, Martin C, and Duck L, &ldquo;Osteonecrosis of the Jaw and Bisphosphonates,&rdquo; <i>N Engl J Med</i>, 2005, 353(1):99-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/16003838/pubmed\" target=\"_blank\" id=\"16003838\">16003838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of The North American Menopause Society,&rdquo; <i>Menopause</i>, 2010, 17(1):25-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20061894/pubmed\" target=\"_blank\" id=\"20061894\">20061894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McClung M, Miller P, Recknor C, et al, &ldquo;Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass: A Randomized Controlled Trial,&rdquo; <i>Obstet Gynecol</i>, 2009, 114(5):999-1007.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20168099/pubmed\" target=\"_blank\" id=\"20168099\">20168099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McMahon RE, Bouquot JE, Glueck CJ, et al, &ldquo;Osteonecrosis: A Multifactorial Etiology,&rdquo; <i>J Oral Maxillofac Surg</i>, 2004, 62(7):904-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/15244000/pubmed\" target=\"_blank\" id=\"15244000\">15244000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17369566\"></a>Michaelson MD, Kaufman DS, Lee H, et al, &ldquo;Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist-Induced Bone Loss in Men With Prostate Cancer,&rdquo; <i>J Clin Oncol</i>, 2007, 25(9):1038-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/17369566/pubmed\" target=\"_blank\" id=\"17369566\">17369566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan GJ, Davies FE, Gregory WM, et al, &ldquo;Effects of Induction and Maintenance Plus Long-Term Bisphosphonates on Bone Disease in Patients With Multiple Myeloma: The Medical Research Council Myeloma IX Trial,&rdquo; <i>Blood</i>, 2012, 119(23):5374-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/22498739/pubmed\" target=\"_blank\" id=\"22498739\">22498739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pereira RM, Carvalho JF, Paula AP, et al, &quot;Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis,&quot; <i>Rev Bras Reumatol</i>, 2012, 52(4):580-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/22885424/pubmed\" target=\"_blank\" id=\"22885424\">22885424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ralston SH, &ldquo;Pathogenesis of Paget's Disease of Bone,&rdquo; <i>Bone</i>, 2008, 43(5):819-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/18672105/pubmed\" target=\"_blank\" id=\"18672105\">18672105</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reclast (zoledronic acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reid DM, Devogelaer JP, Saag K, et al, &ldquo;Zoledronic Acid and Risedronate in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (HORIZON): A Multicentre, Double-Blind, Double-Dummy, Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2009, 373(9671):1253-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/19362675/pubmed\" target=\"_blank\" id=\"19362675\">19362675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reid IR, Miller P, Lyles K, et al, &ldquo;Comparison of a Single Infusion of Zoledronic Acid With Risedronate for Paget's Disease,&rdquo; <i>N Engl J Med</i>, 2005, 353(9):898-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/16135834/pubmed\" target=\"_blank\" id=\"16135834\">16135834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Renouf D, Velazquez-Martin JP, Simpson R, et al, &ldquo;Ocular Toxicity of Targeted Therapies,&rdquo; <i>J Clinl Oncol</i>, 2012, 30(26):3277-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/22649132/pubmed\" target=\"_blank\" id=\"22649132\">22649132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/25234529/pubmed\" target=\"_blank\" id=\"25234529\">25234529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero S, Gralow J, Marx RE, et al, &quot;Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer,&quot; <i>J Clin Oncol</i>, 2006, 2(1):7-14.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sayin M and Yazici G, &ldquo;Hyperparathyroidism Secondary to Zoledronic Acid Infusion: Case Report,&rdquo; <i>Support Care Cancer</i>, 2009, 17(5):469-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/19205753/pubmed\" target=\"_blank\" id=\"19205753\">19205753</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. <i>Kidney Int</i>. 2004;65(1):304-309.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/14675064/pubmed\" target=\"_blank\" id=\"14675064\">14675064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sellmeyer DE, &ldquo;Atypical Fractures as a Potential Complication of Long-term Bisphosphonate Therapy,&rdquo; <i>JAMA</i>, 2010, 304(13):1480-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20924014/pubmed\" target=\"_blank\" id=\"20924014\">20924014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shane E, Burr D, Ebeling PR, et al, &ldquo;Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research,&rdquo; <i>J Bone Miner Res</i>, 2010, 25(11):2267-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/20842676/pubmed\" target=\"_blank\" id=\"20842676\">20842676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singer FR, Bone HG, Hosking DJ, et al. Paget's disease of bone: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2014;99(12):4408-4422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/25406796/pubmed\" target=\"_blank\" id=\"25406796\">25406796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12771706\"></a>Smith MR, Eastham J, Gleason DM, et al, &ldquo;Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer,&rdquo; <i>J Urol</i>, 2003, 169(6):2008-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/12771706/pubmed\" target=\"_blank\" id=\"12771706\">12771706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stathopoulos IP, Liakou CG, Katsalira A, et al, &quot;The Use of Bisphosphonates in Women Prior to or During Pregnancy and Lactation,&quot; <i>Hormones (Athens)</i>, 2011, 10(4):280-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/22281884/pubmed\" target=\"_blank\" id=\"22281884\">22281884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tarassoff P and Csermak K, &ldquo;Avascular Necrosis of the Jaws: Risk Factors in Metastatic Cancer Patients,&rdquo; <i>J Oral Maxillofac Surg</i>, 2003, 61(10):1238-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/14586868/pubmed\" target=\"_blank\" id=\"14586868\">14586868</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whyte MP, &ldquo;Clinical Practice. Paget's Disease of Bone,&rdquo; <i>N Engl J Med</i>, 2006, 355(6):593-600.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/16899779/pubmed\" target=\"_blank\" id=\"16899779\">16899779</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Poznak CH, Temin S, Yee GC, et al, &ldquo;American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 2011, 29(9):1221-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zoledronic-acid-drug-information/abstract-text/21343561/pubmed\" target=\"_blank\" id=\"21343561\">21343561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zoledronic acid powder for injection [package insert]. Detroit, MI: Caraco; November 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zometa (zoledronic acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9902 Version 213.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F235968\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F235969\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F236015\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F235972\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F235973\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F235974\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F235975\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F235946\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F235932\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10076370\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11441699\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F235948\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132718\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F235947\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25484313\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6136763\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F235938\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F235951\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F235936\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300240\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F235940\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F235942\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F235954\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2998081\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F235955\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F235944\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F21303677\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F235935\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F235950\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F235953\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F235956\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9902|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=zoledronic-acid-patient-drug-information\" class=\"drug drug_patient\">Zoledronic acid: Patient drug information</a></li></ul></div></div>","javascript":null}